New Studies Continue to Validate Medical Marijuana, Inc.’s (OTC: MJNA) RSHO-X Nutraceutical Brand in Mexico


Ryan Allway

April 5th, 2017

News, Top News


Cannabidiol (“CBD”) is being increasingly recognized as a breakthrough cannabinoid compound capable of treating a variety of difficult-to-treat medical conditions. For example, refractory epilepsy (“RE”) is a type of epilepsy that is impossible to treat with traditional anti-epileptic medications, leaving patients with few treatment options. New research suggests that CBD oils could produce meaningful results or even eliminate seizures altogether.

In this article, we will take a look at new studies that have demonstrated the effectiveness of Medical Marijuana Inc.’s (OTC Pink: MJNA) RSHO-X™ in treating serious medical conditions.

Clinical Studies Show Efficacy

Medical Marijuana Inc.’s RSHO-X™ is being used in a growing number of studies designed to show how cannabidiol (“CBD”) can help treat serious medical conditions.

The company initially released a PR about a study conducted by Mexican pediatric neurologist Dr. Saul Garza Morales, which evaluated the effects of RSHO-X™ on treating children with severe epilepsy. The 39-patient study found that those taking 5-7mg of CBD/kg experienced an 84% reduction in motor seizures with seven reporting complete elimination of any seizures over a four month period without any adverse side-effects.

On April 5th, the Por Grace Foundation out of Mexico released news of a new survey of Mexican parents of children with refractory epilepsy. The 43-family survey found that over 80% of children experienced a reduction in convulsions following the use of CBD oil and more than 70% of the families used the company’s RSHO-X™ to treat the condition. RSHO-X™ is currently the only legal option for parents looking to import CBD oil with approval from COFEPRIS – the government’s healthcare arm. Most significantly, over 20% of patients decreased the amount of anti-epileptic pharmaceuticals they were taking due to positive results from the cannabidiol.

Epilepsy is a common and chronic neurological disorder that affects over 50 million people worldwide. In Mexico, 1.5 million patients have epilepsy with 80% of patients receiving inadequate treatment and 30% having refractory epilepsy, which fails to respond to common anti-epileptic drugs. Medical Marijuana’s RSHO-X™ is designed to address these patient populations with an effective and affordable alternative.

Building a Grassroots Brand

Medical Marijuana Inc. has built a grassroots brand for its RSHO-X™ and related products across Mexico, Brazil, Paraguay, Argentina, and other countries/territories.

The company begins by securing importation rights into these countries, which helps set its brands apart from unlicensed competitors. Then, the company validates its products by working with physicians and researchers to demonstrate the effectiveness of CBD oils in treating a variety of different conditions. And finally, the company works to raise awareness of the treatment and commercialize the products within the countries.

Mexico may be the company’s initial target for these activities, but similar efforts are ongoing in countries like Brazil where it has already secured importation permits. In May 2015, the Brazilian government approved RSHO™ products as a prescription for approved medical indications including epilepsy. The country’s health authority – ANVISA – has issued a statement on its website and explains how to apply for an import certificate.

These grassroots efforts could pay off over the long-run as the company differentiates its products from the competition and establishes positive relationships with government health authorities. Investors have already begun to see some revenue flow through its HempMeds subsidiaries, but the real value could become more apparent over time as its awareness efforts ramp up and more patients become aware of their options.

Looking Ahead

Medical Marijuana Inc. (OTC Pink: MJNA) represents a compelling investment opportunity within the burgeoning CBD space. With exclusive permits to import RSHO™ into a growing number of countries and mounting clinical evidence, the company is rapidly approaching a tipping point where it can begin educating potential patients and converting them into paying customers while treating a growing number of severe medical conditions.

For more information, visit the company’s website or CannabisFN’s company profile.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading